Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Landen CN, Buckanovich RJ, Sill MW, Mannel RS, Walker JL, DiSilvestro PA, Mathews CA, Mutch DG, Hernandez ML, Martin LP, Bishop E, Gill SE, Gordinier ME, Burger RA, Aghajanian C, Liu JF, Moore KN, Bookman MA. Landen CN, et al. Among authors: martin lp. J Clin Oncol. 2024 Jul 20;42(21):2537-2545. doi: 10.1200/JCO.23.02076. Epub 2024 May 22. J Clin Oncol. 2024. PMID: 38776484 Clinical Trial.
Ovarian cancer, version 3.2012.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49. doi: 10.6004/jnccn.2012.0140. J Natl Compr Canc Netw. 2012. PMID: 23138163
Ovarian cancer, version 2.2013.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M; National comprehensive cancer networks. Morgan RJ Jr, et al. J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209. doi: 10.6004/jnccn.2013.0142. J Natl Compr Canc Netw. 2013. PMID: 24142821
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. Martin LP, et al. Gynecol Oncol. 2014 Mar;132(3):526-30. doi: 10.1016/j.ygyno.2013.12.018. Epub 2013 Dec 18. Gynecol Oncol. 2014. PMID: 24361733 Free PMC article. Clinical Trial.
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Chan JK, et al. Among authors: martin lp. N Engl J Med. 2016 Feb 25;374(8):738-48. doi: 10.1056/NEJMoa1505067. N Engl J Med. 2016. PMID: 26933849 Free PMC article. Clinical Trial.
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Monk BJ, et al. Among authors: martin lp. J Clin Oncol. 2016 Jul 1;34(19):2279-86. doi: 10.1200/JCO.2015.65.8153. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217446 Free PMC article. Clinical Trial.
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Moore KN, et al. Among authors: martin lp. J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029313 Free PMC article. Clinical Trial.
CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.
Ng CS, Zhang Z, Lee SI, Marques HS, Burgers K, Su F, Bauza J, Mannel RS, Walker JL, Huh WK, Rubin SC, DiSilvestro P, Martin LP, Chan JK, Bookman MA, Coleman RL, Lee TY. Ng CS, et al. Among authors: martin lp. Clin Cancer Res. 2017 Jul 15;23(14):3684-3691. doi: 10.1158/1078-0432.CCR-16-1859. Epub 2017 Feb 7. Clin Cancer Res. 2017. PMID: 28174234 Free PMC article. Clinical Trial.
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Martin LP, et al. Gynecol Oncol. 2017 Nov;147(2):402-407. doi: 10.1016/j.ygyno.2017.08.015. Epub 2017 Aug 24. Gynecol Oncol. 2017. PMID: 28843653 Free PMC article. Clinical Trial.
88 results